Clinical role of Bcl-2, Bax, or p53 overexpression in peripheral T-cell lymphomas

[1]  E. Iannitto,et al.  Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. , 2004, Blood.

[2]  T. McDonnell,et al.  BCL‐2 family proteins in peripheral T‐cell lymphomas: correlation with tumour apoptosis and proliferation , 2003, The Journal of pathology.

[3]  S. Sohn,et al.  Prognostic significance of bcl‐2, bax, and p53 expression in diffuse large B‐cell lymphoma , 2003, American journal of hematology.

[4]  C. Meijer,et al.  Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. , 2002, Blood.

[5]  A. Ranki,et al.  Proapoptotic and antiapoptotic markers in cutaneous T‐cell lymphoma skin infiltrates and lymphomatoid papulosis , 2001, The British journal of dermatology.

[6]  E. Pescarmona,et al.  p53 over‐expression identifies a subset of nodal peripheral T‐cell lymphomas with a distinctive biological profile and poor clinical outcome , 2001, The Journal of pathology.

[7]  P. Brousset,et al.  Bcl-2 expression in anaplastic large cell lymphoma. , 2001, The American journal of pathology.

[8]  S. Lowe,et al.  Apoptosis in cancer. , 2000, Carcinogenesis.

[9]  G Flandrin,et al.  World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  G Flandrin,et al.  The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  R. Kanamaru,et al.  Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma. , 1999, Anti-cancer drug design.

[12]  J Hermans,et al.  Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. , 1998, Blood.

[13]  C. Kittas,et al.  Prognostic relevance of apoptotic cell death in non‐Hodgkin's lymphomas: a multivariate survival analysis including Ki67 and p53 oncoprotein expression , 1998, Histopathology.

[14]  R. Gascoyne,et al.  Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[15]  J C Reed,et al.  Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. , 1997, Blood.

[16]  J Hermans,et al.  Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Rottenberg,et al.  Bcl‐2, Bax and p53 expression in B‐CLL in relation to in vitro survival and clinical progression , 1996, International journal of cancer.

[18]  Yi-Song Wang,et al.  bcl-2 inhibits wild-type p53-triggered apoptosis but not G1 cell cycle arrest and transactivation of WAF1 and bax. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[19]  E. White,et al.  Bcl-2 blocks p53-dependent apoptosis , 1994, Molecular and cellular biology.

[20]  M. Piris,et al.  p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. , 1994, British Journal of Cancer.

[21]  H. Saito,et al.  Mutations of the p53 gene in B-cell lymphoma. , 1993, Leukemia & lymphoma.

[22]  M. Raffeld,et al.  Oncogene rearrangements in chronic B-cell leukemia. , 1991, Blood.

[23]  M. Cleary,et al.  The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation , 1989, Molecular and cellular biology.

[24]  B. Wilkes,et al.  The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. , 1988, Blood.

[25]  John Calvin Reed,et al.  BCL‐2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy , 1996, Journal of cellular biochemistry.

[26]  J Diebold,et al.  Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 1996, Blood.

[27]  P. Gaulard,et al.  Prognostic Significance of bcl-2 Protein Expression in Aggressive Non-Hodgkin's Lymphoma , 1996 .